People with sickle cell disease have few effective treatment options. The FDA has only approved two drugs — 20 years apart — to treat the inherited blood disorder. Efforts to develop a cure for sickle cell disease using gene therapy or genome-editing have shown early promise but are still years away from being proven.

A new and novel medicine from Global Blood Therapeutics (GBT), a small biotech based south of San Francisco, could soon fill that sickle cell treatment gap. A late-stage clinical trial is nearing an interim but important readout before the end of the second quarter.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Early on some had concerns not just about potential hypoxia but also b/c of the aldehyde-based chemistry. I have not heard about this concern lately. Is that something that you have heard come up?

    So far I think even with the small N reported on to date the bio-marker data are pretty convincing. Small N is a big issue when evaluating safety though so this is what I worry about most. Pretty devastating disease so would assume AE bar would be relatively high to derail development?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy